Sinusitis - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 93
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S38409ACAA8EN
Leaflet:

Download PDF Leaflet

Sinusitis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Sinusitis - Pipeline Review, H2 2016’, provides an overview of the Sinusitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Sinusitis
  • The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects
  • The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sinusitis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sinusitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Sinusitis Overview
Therapeutics Development
Pipeline Products for Sinusitis - Overview
Sinusitis - Therapeutics under Development by Companies
Sinusitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Sinusitis - Products under Development by Companies
Sinusitis - Companies Involved in Therapeutics Development
AmpliPhi Biosciences Corporation
F. Hoffmann-La Roche Ltd.
Knopp Biosciences LLC
Kyorin Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
Merck & Co., Inc.
Oticpharma Ltd
Paratek Pharmaceuticals, Inc.
Pfizer Inc.
Quorum Innovations LLC
Regeneron Pharmaceuticals Inc
Therabron Therapeutics, Inc.
Sinusitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABSA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexpramipexole dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KRPAM-1977X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCL-1404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06817024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qi-117 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Sinusitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chronic Rhinosinusitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sinusitis - Dormant Projects
Sinusitis - Product Development Milestones
Featured News & Press Releases
Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress
Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus
Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab
Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association
Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01
Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 93

LIST OF TABLES

Number of Products under Development for Sinusitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Sinusitis - Pipeline by AmpliPhi Biosciences Corporation, H2 2016
Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Sinusitis - Pipeline by Knopp Biosciences LLC, H2 2016
Sinusitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Sinusitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
Sinusitis - Pipeline by Merck & Co., Inc., H2 2016
Sinusitis - Pipeline by Oticpharma Ltd, H2 2016
Sinusitis - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016
Sinusitis - Pipeline by Pfizer Inc., H2 2016
Sinusitis - Pipeline by Quorum Innovations LLC, H2 2016
Sinusitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Sinusitis - Pipeline by Therabron Therapeutics, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Sinusitis - Dormant Projects, H2 2016 86

LIST OF FIGURES

Number of Products under Development for Sinusitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Sinusitis - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 80 pages
Pergamum AB - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 23 pages

Ask Your Question

Sinusitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: